---
title: "Akari Therapeutics, Plc (AKTX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AKTX.US.md"
symbol: "AKTX.US"
name: "Akari Therapeutics, Plc"
industry: "Biotechnology"
datetime: "2026-04-15T03:43:07.500Z"
locales:
  - [en](https://longbridge.com/en/quote/AKTX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AKTX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AKTX.US.md)
---

# Akari Therapeutics, Plc (AKTX.US)

## Company Overview

Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.akaritx.com](https://www.akaritx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -12.25 | 467 | - | - | - |
| PB | 7.48 | 367 | 1.72 | 1.04 | 0.53 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-08T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 75% |
| Hold | 1 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.63 |
| Highest Target | 280.00 |
| Lowest Target | 27.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AKTX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AKTX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AKTX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AKTX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**